Precision BioSciences DTIL Stock
Precision BioSciences Price Chart
Precision BioSciences DTIL Financial and Trading Overview
Precision BioSciences stock price | 4.4 USD |
Previous Close | 0.38 USD |
Open | 0.39 USD |
Bid | 0.43 USD x 3000 |
Ask | 0.43 USD x 1000 |
Day's Range | 0.39 - 0.44 USD |
52 Week Range | 0.28 - 1.54 USD |
Volume | 1.55M USD |
Avg. Volume | 955.78K USD |
Market Cap | 51.93M USD |
Beta (5Y Monthly) | 1.36 |
PE Ratio (TTM) | N/A |
EPS (TTM) | 1.04 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 2.63 USD |
DTIL Valuation Measures
Enterprise Value | -46444896 USD |
Trailing P/E | N/A |
Forward P/E | -1.2474285 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 0.9931153 |
Price/Book (mrq) | 1.7394423 |
Enterprise Value/Revenue | -0.888 |
Enterprise Value/EBITDA | 0.649 |
Trading Information
Precision BioSciences Stock Price History
Beta (5Y Monthly) | 1.36 |
52-Week Change | N/A |
S&P500 52-Week Change | N/A |
52 Week High | 1.54 USD |
52 Week Low | 0.28 USD |
50-Day Moving Average | 0.36 USD |
200-Day Moving Average | 0.66 USD |
DTIL Share Statistics
Avg. Volume (3 month) | 955.78K USD |
Avg. Daily Volume (10-Days) | 1.03M USD |
Shares Outstanding | 118.94M |
Float | 93.54M |
Short Ratio | 0.73 |
% Held by Insiders | 14.89% |
% Held by Institutions | 43.76% |
Shares Short | 606.9K |
Short % of Float | 0.59% |
Short % of Shares Outstanding | 0.52% |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | September 30, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -140.60% |
Operating Margin (ttm) | -94.23% |
Gross Margin | 100.00% |
EBITDA Margin | -136.77% |
Management Effectiveness
Return on Assets (ttm) | -22.64% |
Return on Equity (ttm) | -153.81% |
Income Statement
Revenue (ttm) | 52.29M USD |
Revenue Per Share (ttm) | 0.46 USD |
Quarterly Revenue Growth (yoy) | 78.20% |
Gross Profit (ttm) | 25.1M USD |
EBITDA | -71515000 USD |
Net Income Avi to Common (ttm) | -87248000 USD |
Diluted EPS (ttm) | -0.86 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 122.23M USD |
Total Cash Per Share (mrq) | 1.03 USD |
Total Debt (mrq) | 23.86M USD |
Total Debt/Equity (mrq) | 82.09 USD |
Current Ratio (mrq) | 2.881 |
Book Value Per Share (mrq) | 0.251 |
Cash Flow Statement
Operating Cash Flow (ttm) | -97534000 USD |
Levered Free Cash Flow (ttm) | -71768752 USD |
Profile of Precision BioSciences
Country | United States |
State | NC |
City | Durham |
Address | 302 East Pettigrew Street |
ZIP | 27701 |
Phone | 919 314 5512 |
Website | https://www.precisionbiosciences.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 115 |
Precision BioSciences, Inc., a clinical stage gene editing company, develops ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases in the United States. The company offers ARCUS, a genome editing platform to cure genetic disorders. It also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, an azercabtagene zapreleucel, for the treatment of acute lymphoblastic leukemia and B-cell precursor acute lymphoblastic leukemia; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T cell candidate targeting B-cell maturation antigen for relapsed or refractory (R/R) multiple myeloma in combination with nirogacestat, a gamma secretase inhibitor. The company has development and commercial license agreements with Les Laboratoires Servier to develop allogeneic CAR T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
Q&A For Precision BioSciences Stock
What is a current DTIL stock price?
Precision BioSciences DTIL stock price today per share is 4.4 USD.
How to purchase Precision BioSciences stock?
You can buy DTIL shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Precision BioSciences?
The stock symbol or ticker of Precision BioSciences is DTIL.
Which industry does the Precision BioSciences company belong to?
The Precision BioSciences industry is Biotechnology.
How many shares does Precision BioSciences have in circulation?
The max supply of Precision BioSciences shares is 10.48M.
What is Precision BioSciences Price to Earnings Ratio (PE Ratio)?
Precision BioSciences PE Ratio is 4.23076960 now.
What was Precision BioSciences earnings per share over the trailing 12 months (TTM)?
Precision BioSciences EPS is 1.04 USD over the trailing 12 months.
Which sector does the Precision BioSciences company belong to?
The Precision BioSciences sector is Healthcare.
Precision BioSciences DTIL included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
NASDAQ Composite IXIC | 15603.26 USD — |
+0.1
|
10.08B USD — | 14784.03 USD — | 16292.28 USD — | — - | 10.08B USD — |
NASDAQ Global Select Market Com NQGS | 7634.31 USD — |
+0.11
|
— — | 7233.89 USD — | 7972.89 USD — | — - | — — |
NASDAQ Biotechnology NBI | 3856.67 USD — |
-1.22
|
— — | 3700.88 USD — | 3966.57 USD — | — - | — — |
NASDAQ HealthCare IXHC | 865.57 USD — |
-0.49
|
— — | 828.4 USD — | 890 USD — | — - | — — |
Stlmt ID NASDAQ Biotechnology NBX | 4153.28 USD — |
+1.21
|
— — | 4281.91 USD — | 4648.11 USD — | — - | — — |
- {{ link.label }} {{link}}